IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published Mar 27, 2026
Medical Professional
EMPOWER Safety
Dr. Joshua Richter reviews the safety profile and AE management of MeziKd (Video 2/3)
Joshua Richter, MD
Dr. Joe Mendez reviews the adjuvant vorasidenib patient profile in low-grade gliomas (Video 2/3)
Joe Mendez, MD
Dr. Sandip Patel discusses the impact of adding chemotherapy in patients progressing on 1L osimertinib. (Video 1/3)
Sandip Patel, MD
Dr. Laura van ‘t Veer reviews ctDNA clearance at week 3 as an early indicator in breast cancer (Video 2/3)
Laura van 't Veer, PhD
Dr. Joshua Richter discusses the MOA of CELMoDs and efficacy of MeziKd (Video 1/3)
Joshua Richter, MD
Dr. Joe Mendez reviews vorasidenib for IDH mutant low-grade gliomas (Video 1/3)
Joe Mendez, MD